SignatureFD’s Cue Biopharma CUE Stock Holding History

SignatureFD’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3	Closed	-$1K	–	3135
2021 Q3	$1K	Buy	+3	New	+$1.05K	﹤0.01%	2800
2020 Q3	–	Sell	-3	Closed	-$2K	–	2626
2020 Q2	$2K	Buy	+3	New	+$2.17K	﹤0.01%	2103

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

SignatureFD's CUE Position: Q4 2021 in Review

SignatureFD sold out of Cue Biopharma (CUE) in Q4 2021, closing a stake of 3 shares — an estimated $1K sold.

SignatureFD first reported a position in CUE in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q2 2020. 90 funds tracked by Wall St. Rank hold CUE as of Q4 2021.

SignatureFD reported no remaining Cue Biopharma position as of Q4 2021 after selling out during the quarter.
SignatureFD sold 3 Cue Biopharma shares in Q4 2021, an estimated $1K.
SignatureFD first reported a position in Cue Biopharma in Q2 2020 and held it in 2 quarters.
SignatureFD's Cue Biopharma position peaked at $2K in Q2 2020.
90 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2021.

Based on SignatureFD's 13F filing for Q4 2021, filed 25 Jan 2022.